Biocon Ltd., a biopharmaceutical company based in India, develops, manufactures and supplies products to treat diabetes, cancer, and autoimmune conditions. Last week, Biocon launched KRABEVA®, a bevacizumab biosimilar for the treatment of metastatic colorectal cancer and other types of lung, kidney, cervical, ovarian, and brain cancers in India.

Biocon reports that KRABEVA® is being introduced “with an innovative temperature-sensitive packaging that includes thermo-chromic stickers, which change colour irreversibly if the cold chain temperature is not maintained. This first-of-its-kind ‘Qual Check’ feature ensures quality check of the product up to the point of administration to the patient.” Biocon states in its press release that “[t]his will provide greater confidence to physicians and healthcare professionals about the quality of the product they are dispensing and will enable better patient safety.”